Abstract
Clinical syndrome of heart failure
Patients with congestive heart failure (CHF) complain of reduced exercise capacity, dyspnea on exertion, orthopnea and lower extremity edema [22, 33] . These symptoms are secondary to a reduction in cardiac function, and to date, despite a number of advances in our understanding of the molecular mechanism(s) that result in CHF, the mortality for this disease is high and the only known cure is cardiac transplantation [14, 22, 33] . Thus, drug regimens are aimed at prolonging survival and reducing symptoms [14, 22, 33] .
A number of abnormalities of cardiac muscle and the contractile proteins have been documented, and the cardiac phenotype in CHF is the subject of intense investigation (reviewed in [57, 65] . However, CHF is also characterized by an elevated baseline vascular tone and an impaired response to nitric oxide mediated vasodilatation [22, 52] . These changes in the vasculature are not compensatory, but rather impair the heart's ability to generate cardiac output sufficient to meet demand, and further exacerbate symptoms. The mechanism that leads to these changes in the vasculature is unknown, and whether changes in the contractile phenotype of vascular smooth muscle are responsible for these abnormalities had, until recently , not yet been the subject of investigation. [33, 42] [68, 69] 
Neuroendocrine activation of the renin-angiotensin system (RAS) has been implicated in contributing to the abnormal vasoconstriction in CHF
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